Back to Search
Start Over
Is fluorescein-guided technique able to help in resection of high-grade gliomas?
- Source :
-
Neurosurgical focus [Neurosurg Focus] 2014 Feb; Vol. 36 (2), pp. E5. - Publication Year :
- 2014
-
Abstract
- Object: Fluorescein, a dye that is widely used as a fluorescent tracer, accumulates in cerebral areas where the blood-brain barrier is damaged. This quality makes it an ideal dye for the intraoperative visualization of high-grade gliomas (HGGs). The authors report their experience with a new fluorescein-guided technique for the resection of HGGs using a dedicated filter on the surgical microscope.<br />Methods: The authors initiated a prospective Phase II trial (FLUOGLIO) in September 2011 with the objective of evaluating the safety of fluorescein-guided surgery for HGGs and obtaining preliminary evidence regarding its efficacy for this purpose. To be eligible for participation in the study, a patient had to have suspected HGG amenable to complete resection of the contrast-enhancing area. The present report is based on the analysis of the short- and long-term results in 20 consecutive patients with HGGs (age range 45-74 years), enrolled in the study since September 2011. In all cases fluorescein (5-10 mg/kg) was injected intravenously after intubation. Tumor resection was performed with microsurgical technique and fluorescence visualization by means of BLUE 400 or YELLOW 560 filters on a Pentero microscope.<br />Results: The median preoperative tumor volume was 30.3 cm(3) (range 2.4-87.8 cm(3)). There were no adverse reactions related to fluorescein administration. Complete removal of contrast-enhanced tumor was achieved in 80% of the patients. The median duration of follow-up was 10 months. The 6-months progression-free survival rate was 71.4% and the median survival was 11 months.<br />Conclusions: Analysis of these 20 cases suggested that fluorescein-guided technique with a dedicated filter on the surgical microscope is safe and allows a high rate of complete resection of contrast-enhanced tumor as determined on early postoperative MRI. Clinical trial registration no.: 2011-002527-18 (EudraCT).
- Subjects :
- Aged
Brain Neoplasms mortality
Female
Fluorescent Dyes
Follow-Up Studies
Glioblastoma mortality
Humans
Male
Microsurgery methods
Middle Aged
Prospective Studies
Survival Rate trends
Brain Neoplasms diagnosis
Brain Neoplasms surgery
Fluorescein
Glioblastoma diagnosis
Glioblastoma surgery
Neuronavigation methods
Subjects
Details
- Language :
- English
- ISSN :
- 1092-0684
- Volume :
- 36
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Neurosurgical focus
- Publication Type :
- Academic Journal
- Accession number :
- 24484258
- Full Text :
- https://doi.org/10.3171/2013.11.FOCUS13487